loading
Schlusskurs vom Vortag:
$22.82
Offen:
$23.04
24-Stunden-Volumen:
83,711
Relative Volume:
0.22
Marktkapitalisierung:
$304.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.48M
KGV:
-15.05
EPS:
-1.4641
Netto-Cashflow:
$-8.59M
1W Leistung:
+2.98%
1M Leistung:
-4.16%
6M Leistung:
+96.19%
1J Leistung:
+150.62%
1-Tages-Spanne:
Value
$22.00
$23.36
1-Wochen-Bereich:
Value
$22.05
$24.82
52-Wochen-Spanne:
Value
$7.78
$34.10

Greenwich Lifesciences Inc Stock (GLSI) Company Profile

Name
Firmenname
Greenwich Lifesciences Inc
Name
Telefon
203-434-3290
Name
Adresse
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Name
Mitarbeiter
8
Name
Twitter
Name
Nächster Verdiensttermin
2026-04-21
Name
Neueste SEC-Einreichungen
Name
GLSI's Discussions on Twitter

Compare GLSI vs VRTX, REGN, ARGX, ALNY, INSM

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
GLSI icon
GLSI
Greenwich Lifesciences Inc
22.00 316.16M 0 -19.48M -8.59M -1.4641
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
433.53 111.45B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
761.09 80.54B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
747.05 46.32B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
330.56 42.29B 3.71B 313.75M 465.38M 2.2571
INSM icon
INSM
Insmed Inc
163.57 35.01B 606.42M -1.28B -997.58M -6.403

Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-08-20 Eingeleitet Noble Capital Markets Outperform
2021-09-01 Eingeleitet H.C. Wainwright Buy

Greenwich Lifesciences Inc Aktie (GLSI) Neueste Nachrichten

pulisher
Mar 31, 2026

Greenwich LifeSciences Delays Annual SEC Filing - tipranks.com

Mar 31, 2026
pulisher
Mar 31, 2026

Greenwich LifeSciences (GLSI) notifies SEC of late 10-K, cites higher R&D - Stock Titan

Mar 31, 2026
pulisher
Mar 30, 2026

Sell Signal: What are the future prospects of Greenwich LifeSciences Inc2026 Market Overview & Long-Term Investment Growth Plans - baoquankhu1.vn

Mar 30, 2026
pulisher
Mar 30, 2026

(GLSI) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com

Mar 30, 2026
pulisher
Mar 27, 2026

Greenwich LifeSciences (GLSI) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat

Mar 27, 2026
pulisher
Mar 26, 2026

Aug Analyst Calls: What are the future prospects of Greenwich LifeSciences IncPortfolio Value Summary & Real-Time Market Trend Scan - baoquankhu1.vn

Mar 26, 2026
pulisher
Mar 23, 2026

GLSI Technical Analysis | Trend, Signals & Chart Patterns | GREENWICH LIFESCIENCES INC (NASDAQ:GLSI) - ChartMill

Mar 23, 2026
pulisher
Mar 22, 2026

If You Invested $1,000 in Greenwich Lifesciences Inc (GLSI) - Stock Titan

Mar 22, 2026
pulisher
Mar 21, 2026

Retail Trends: Is Greenwich LifeSciences Inc undervalued by DCF analysisGold Moves & Weekly Top Performers Watchlists - baoquankhu1.vn

Mar 21, 2026
pulisher
Mar 20, 2026

Treasury Yields: Is Greenwich LifeSciences Inc a turnaround storyWeekly Profit Analysis & Long Hold Capital Preservation Plans - baoquankhu1.vn

Mar 20, 2026
pulisher
Mar 19, 2026

Greenwich LifeSciences expands Phase III trial to City of Hope sites - ca.investing.com

Mar 19, 2026
pulisher
Mar 19, 2026

Greenwich LifeSciences Inc initiates new US clinical sites for Flamingo-01 phase III trial - marketscreener.com

Mar 19, 2026
pulisher
Mar 19, 2026

Greenwich LifeSciences, Inc. Announces Addition of City of Hope to Flamingo-01 - marketscreener.com

Mar 19, 2026
pulisher
Mar 19, 2026

Greenwich LifeSciences Expands FLAMINGO-01 Trial to City of Hope - National Today

Mar 19, 2026
pulisher
Mar 19, 2026

Greenwich LifeSciences expands Phase III trial to City of Hope sites By Investing.com - Investing.com India

Mar 19, 2026
pulisher
Mar 19, 2026

Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01 - ChartMill

Mar 19, 2026
pulisher
Mar 19, 2026

Liquidity Mapping Around (GLSI) Price Events - news.stocktradersdaily.com

Mar 19, 2026
pulisher
Mar 19, 2026

Greenwich LifeSciences to present trial data at AACR meeting By Investing.com - Investing.com South Africa

Mar 19, 2026
pulisher
Mar 18, 2026

Greenwich LifeSciences to present trial data at AACR meeting - Investing.com

Mar 18, 2026
pulisher
Mar 18, 2026

Greenwich Lifesciences provides update on upcoming AACR meeting - marketscreener.com

Mar 18, 2026
pulisher
Mar 18, 2026

Greenwich Lifesciences Provides Update On Upcoming Aacr Meeting - TradingView

Mar 18, 2026
pulisher
Mar 18, 2026

Greenwich LifeSciences Provides Update on Upcoming AACR Meeting - manilatimes.net

Mar 18, 2026
pulisher
Mar 18, 2026

Greenwich LifeSciences, Inc. Announces Presentation of FLAMINGO-01 Phase III Clinical Trial Data at AACR Meeting 2026 - Quiver Quantitative

Mar 18, 2026
pulisher
Mar 18, 2026

Greenwich LifeSciences to share AACR Meeting plans - Traders Union

Mar 18, 2026
pulisher
Mar 18, 2026

Greenwich LifeSciences reports reduced cancer recurrence in trial By Investing.com - Investing.com South Africa

Mar 18, 2026
pulisher
Mar 17, 2026

Why is GLSI stock rising today? - MSN

Mar 17, 2026
pulisher
Mar 17, 2026

Breakthrough in Clinical Trial Data: Biopharmaceutical company Greenwich Lifesciences Inc (NASDAQ: GLSI) recently announced the latest analysis results of its core immunotherapy GP2 in adjuvant treatment for breast cancer. - Bitget

Mar 17, 2026
pulisher
Mar 17, 2026

Why Is GLSI Stock Rising Today? - Mena FN

Mar 17, 2026
pulisher
Mar 17, 2026

Greenwich LifeSciences reports reduced cancer recurrence in trial - Investing.com

Mar 17, 2026
pulisher
Mar 17, 2026

Greenwich LifeSciences provides update showing continued reduction in recurrence rate in the open label arm of Flamingo-01 - marketscreener.com

Mar 17, 2026
pulisher
Mar 17, 2026

Greenwich Lifesciences Provides Update Showing Continued Reduction In Recurrence Rate In The Open Label Arm Of Flamingo-01 - TradingView

Mar 17, 2026
pulisher
Mar 17, 2026

Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01 - manilatimes.net

Mar 17, 2026
pulisher
Mar 17, 2026

Greenwich LifeSciences Provides Update Showing Continued - GlobeNewswire

Mar 17, 2026
pulisher
Mar 17, 2026

Greenwich LifeSciences begins using commercial GP2 at US sites By Investing.com - Investing.com Australia

Mar 17, 2026
pulisher
Mar 16, 2026

Greenwich LifeSciences begins using commercial GP2 at US sites - Investing.com

Mar 16, 2026
pulisher
Mar 16, 2026

Greenwich LifeSciences Provides Update on Phase III Clinical Trial FLAMINGO-01 and Commercial Manufacturing of GP2 - Quiver Quantitative

Mar 16, 2026
pulisher
Mar 16, 2026

Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01 - GlobeNewswire

Mar 16, 2026
pulisher
Mar 11, 2026

Big Money Moves: Is Greenwich LifeSciences Inc undervalued by DCF analysisPortfolio Performance Summary & Free Community Supported Trade Ideas - baoquankhu1.vn

Mar 11, 2026
pulisher
Mar 10, 2026

Greenwich LifeSciences (NASDAQ:GLSI) Trading Up 11.6% – Should You Buy? - Defense World

Mar 10, 2026
pulisher
Mar 10, 2026

Greenwich LifeSciences (NASDAQ:GLSI) Trading Up 11.6%Should You Buy? - MarketBeat

Mar 10, 2026
pulisher
Mar 08, 2026

Why (GLSI) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Mar 08, 2026
pulisher
Mar 06, 2026

Why did Greenwich LifeSciences stock soar pre-market today? - MSN

Mar 06, 2026
pulisher
Mar 06, 2026

ETF Watch: Is Greenwich LifeSciences Inc a turnaround storyWeekly Investment Recap & Free Technical Confirmation Trade Alerts - baoquankhu1.vn

Mar 06, 2026
pulisher
Mar 06, 2026

Market Review: Is Greenwich LifeSciences Inc a stock for growth or value investorsMarket Activity Summary & High Conviction Buy Zone Alerts - baoquankhu1.vn

Mar 06, 2026
pulisher
Mar 06, 2026

GLSI Should I Buy - Intellectia AI

Mar 06, 2026

Finanzdaten der Greenwich Lifesciences Inc-Aktie (GLSI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Greenwich Lifesciences Inc-Aktie (GLSI) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Patel Snehal
CEO and CFO
Jan 12 '26
Buy
27.54
2,900
79,866
5,602,302
Patel Snehal
CEO and CFO
Dec 31 '25
Buy
21.36
4,300
91,848
5,599,402
Patel Snehal
CEO and CFO
Dec 30 '25
Buy
21.73
2,900
63,017
5,595,102
Patel Snehal
CEO and CFO
Dec 18 '25
Buy
12.62
4,100
51,742
5,592,202
Patel Snehal
CEO and CFO
Nov 25 '25
Buy
8.37
4,600
38,502
5,588,102
Patel Snehal
CEO and CFO
Nov 07 '25
Buy
8.43
10,600
89,358
5,583,502
Patel Snehal
CEO and CFO
Oct 31 '25
Buy
9.26
2,300
21,298
5,572,902
Patel Snehal
CEO and CFO
Apr 25 '25
Buy
9.88
3,600
35,568
5,570,602
Patel Snehal
CEO and CFO
Apr 17 '25
Buy
8.98
5,400
48,492
5,567,002
Patel Snehal
CEO and CFO
Apr 07 '25
Buy
9.10
3,600
32,760
5,561,602
$49.55
price down icon 1.90%
$28.34
price up icon 1.08%
$47.79
price down icon 1.05%
$91.15
price up icon 0.08%
ONC ONC
$311.43
price up icon 0.93%
$163.18
price down icon 1.52%
Kapitalisierung:     |  Volumen (24h):